Is BOLT's Q1 2025 EPS forecast a sign of recovery?

**Bolt Biotherapeutics Inc. (BOLT) is not currently forming a sign of recovery in its Q1 2025 EPS forecast.** Here's an analysis based on the latest data and market perspectives:

1. **Expected Q1 2025 EPS and Revenue**: The estimated EPS for Bolt Biotherapeutics in Q1 2025 is -$0.34, with an estimated revenue of $1.02 million for the quarter. This indicates a continued financial challenge for the company.

2. **Analyst Expectations**: Analysts have a "hold" rating on the stock with no "strong buy" or "buy" recommendations, suggesting a cautious outlook. The mean earnings estimate has not changed in the last three months, indicating a lack of optimism for an immediate recovery.
3. **Recent Performance and Challenges**:
- Bolt Biotherapeutics reported a net loss of $15.9 million for Q4 2024, translating to a loss per share of $0.42. This performance reflects ongoing financial strain.
- The company's revenue for Q4 2024 was $0, missing estimates, and there was a significant decrease in collaboration revenue compared to the previous year.
- Despite these challenges, the company has completed enrollment for the highest dose cohort in the BD-001-101 phase 1b/2a study, indicating progress in clinical developments.
4. **Cash Position and Funding**: Bolt Biotherapeutics has a cash position of $70.2 million as of December 31, 2024, which is expected to fund operations through mid-2026. This provides some stability but does not indicate an imminent recovery in earnings.
5. **Market Sentiment and Price Target**: The stock has a consensus price target of $3.50, with a current price below this target. However, the price target does not necessarily reflect a recovery; instead, it suggests a potential for the stock to appreciate from its current level.

In conclusion, the Q1 2025 EPS forecast does not signal a recovery for Bolt Biotherapeutics. The company continues to face significant financial challenges, and while there is some progress in clinical developments, it does not immediately translate to an earnings recovery. Investors should monitor the company's clinical advancements and financial performance closely for signs of recovery.